Accretion Pharmaceuticals IPO
Open SmeCurrent GMP
₹5 (+4.95%)
Price Band
₹ 96 – 101
Lot Size
1200
Issue Size
₹29.75 Cr
Minimum Investment
₹242400 (2400 Shares)
Listing Date
21 May 2025
Subscription
7.73x
About the Company
Accretion Pharmaceuticals Limited, originally established as M/s Accretion Pharmaceuticals, was founded in 2012 by Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra, and Mr. Hardik Mukundbhai Prajapati with the goal of manufacturing healthcare products meeting international standards at competitive prices. The company began as a partnership firm and commenced manufacturing operations in 2014 at its facility located in Ahmedabad, Gujarat.
On October 16, 2023, the firm transitioned into a limited company under the Companies Act, 2013, and was officially incorporated as Accretion Pharmaceuticals Limited on November 29, 2023 (CIN: U21004GJ2023PLC146545).
The company is engaged in the manufacturing and marketing of a wide range of pharmaceutical products including tablets, capsules, oral liquids, external preparations (such as ointments, creams, gels, lotions, shampoos, mouthwashes, and dusting powders), and oral powders (like sachets and dry syrups). Operations include direct sales, contract manufacturing, and loan licensing for various marketers.
Accretion Pharmaceuticals operates in three business verticals:
- Domestic market sales
- Direct export sales
- Sales to merchant exporters under loan license
A significant portion of its products is exported, directly or indirectly, to markets such as Africa, South-East Asia, and Latin America. The company is ISO 9001:2015, ISO 14001:2015, and ISO 22000:2018 certified and is managed by a professional and experienced team.
Promoters
- Mr. Mayur Popatlal Sojitra
- Mr. Harshad Nanubhai Rathod
- Mr. Vivek Ashok Kumar Patel
- Mr. Hardik Mukundbhai Prajapati
Promoters Holding
Holding Pre Issue
100.00%
Holding Post Issue
73.48%
Objects of the Issue
The objects of the present issue of Equity Shares are:
a. Capital expenditure towards purchase of new equipment/machineries, etc.
b. Capital expenditure towards upgradation of existing manufacturing facility;
c. Repayment/prepayment of certain borrowings availed by our Company;
d. Funding working capital requirements; and
e. General Corporate Purpose
Address / Contact Info
Accretion Pharmaceuticals Limited
29 Xcelon Ind Park 1,
B/h, Intas Pharmaceuticals,
Vasna Chacharvadi, Ahmedabad,
Sanand, Gujarat,-382213
Phone: +91-97148 82929
Email: compliance@accretionpharma.com
Website: https://accretionpharma.com/
IPO Snapshot
IPO Timeline (Tentative)
IPO Open Date
Wednesday, 14 May 2025
IPO Close Date
Friday, 16 May 2025
Basis of Allotment
Monday, 19 May 2025
Initiation of Refunds
Tuesday, 20 May 2025
Credit of Shares to Demat
Tuesday, 20 May 2025
Listing Date
Wednesday, 21 May 2025 — NSE & BSE
Important Dates
Open Date
14 May 2025
Close Date
16 May 2025
Basis Of Allotment
19 May 2025
Listing Date
21 May 2025
Financial Performance (₹ in Crores)
| Particular | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 29.34 | 27.05 | 20.58 | 17.74 |
| Revenue | 11.89 | 33.94 | 29.53 | 22.58 |
| Profit After Tax | 1.57 | 3.88 | 0.1 | 0.08 |
| Net Worth | 9.91 | 5.35 | 3.84 | 3.08 |
| Reserve & Surplus | 1.74 | 1.35 | 0 | 0 |
| Total Borrowings | 0 | 0 | 0 | 0 |
EPS Pre
4.74%
EPS Post
2.82%
P/E Pre
21.29
P/E (Post Issue)
35.82x
Company Financial Information
KPI Information (₹ in Crores)
| Particular | KPI as of Mon, Mar 31, 2025. |
|---|---|
| ROE % | 25.2 |
| ROCE % | 11.73 |
| Debt / Equity | 2.52 |
| RoNW % | 72.47 |
| PbW | 0 |
| Pat Margin % | 11.51 |
Return Ratio
IPO Reservations
| Category | Shares Offered | Shares Offered % | Max Allotee |
|---|---|---|---|
| Qualified Institutions | 141700 | 5.48 | 0 |
| Non-Institutional | 1222800 | 47.26 | 0 |
| Retail Investors | 1222800 | 47.26 | 0 |
| Total | 2587300 | 100 | 0 |
Subscription Status ( Fri, 16 May 25 01:28 PM)
| Category | Shares Offered | Shares Bid For | Subscription (x) |
|---|---|---|---|
| Qualified Institutions | 141700 | 1719600 | 12.14x |
| Non-Institutional | 1222800 | 5391600 | 4.41x |
| Retail Investors | 1222800 | 12895200 | 10.55x |
| Total | 2587300 | 20006400 | 7.73x |
Subscription figures are updated periodically and may change until issue closing. Data reflects bids placed across exchanges.
Peer Comparision
No Peer Comparision Available
Lot Size & Investment Details
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 1,200 | 121,200.00 |
| Retail (Max) | 1 | 1,200 | 121,200.00 |
| S-HNI (Min) | 2 | 2,400 | 242,400.00 |
Registrar
Kfin Technologies Limited
04067162222, 04079611000
reachus@kfintech.com
https://www.kfintech.com
Book Running Lead Managers
- Jawa Capital Services Private Limited
RHP Document
DRHP Document
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
Accretion Pharmaceuticals IPO is a Book-building IPO worth ₹29.75 crores. The price band is ₹96 to 101 per share. The IPO opens on Wed, May 14, 2025 and closes on Fri, May 16, 2025. It will be listed on BSE and NSE. Kfin Technologies Limited is the registrar.
The Accretion Pharmaceuticals IPO opens on Wed, May 14, 2025 and closes on Fri, May 16, 2025
Accretion Pharmaceuticals IPO Price Band is ₹96 to 101.
Accretion Pharmaceuticals IPO lot size is 1200, and the minimum amount required for application is ₹242400.
The minimum investment for Accretion Pharmaceuticals IPO is approximately ₹242400 based on the upper price band.
To apply for the Accretion Pharmaceuticals IPO, investors can use the ASBA (Application Supported by Blocked Amount) process via their bank's net banking or apply through UPI using a registered broker or trading app. The IPO is available in retail, HNI, and institutional investor categories. Investors must select the lot size, enter bid details within the price band, and submit their application before the IPO closing date of Fri, May 16, 2025. After submission, funds are blocked until the basis of allotment of Accretion Pharmaceuticals IPO is finalised.
Accretion Pharmaceuticals IPO issue size is ₹29.75 crores.
Accretion Pharmaceuticals IPO allotment date is Sat, Jun 27, 2026.
The registrar for Accretion Pharmaceuticals IPO is Kfin Technologies Limited. Investors can go to Kfin Technologies Limited website for IPO allotment status, refund processing, and other queries related to Accretion Pharmaceuticals IPO through their official website or helpline.
The Accretion Pharmaceuticals IPO GMP (Grey Market Premium) is ₹5 as of Fri, May 16, 2025. Based on the upper price band of ₹101 per share, the estimated Accretion Pharmaceuticals IPO listing price is ₹106, indicating a potential listing gain of approximately 31% over the issue price.